Neoadjuvant radiohormonal therapy for oligo-metastatic prostate cancer: safety and efficacy outcomes from an open-label, dose-escalation, single-center, phase I/II clinical trial

[1]  T. Gevaert,et al.  Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer , 2021, Nature Reviews Urology.

[2]  Guiming Zhang,et al.  Neoadjuvant hormone therapy for patients with high-risk prostate cancer: a systematic review and meta-analysis , 2021, Asian journal of andrology.

[3]  A. Kishan,et al.  Prostate Radiotherapy With Adjuvant Androgen Deprivation Therapy (ADT) Improves Metastasis-Free Survival Compared to Neoadjuvant ADT: An Individual Patient Meta-Analysis. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  Henk G van der Poel,et al.  EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II-2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. , 2020, European urology.

[5]  Ida Sonni,et al.  Impact of 68Ga-PSMA-11 PET/CT on Staging and Management of Prostate Cancer Patients in Various Clinical Settings: A Prospective Single-Center Study , 2020, The Journal of Nuclear Medicine.

[6]  M. Kerin,et al.  Neoadjuvant radiotherapy for rectal cancer management , 2019, World journal of gastroenterology.

[7]  T. H. van der Kwast,et al.  A Phase 1 Pilot Study of Preoperative Radiation Therapy for Prostate Cancer: Long-Term Toxicity and Oncologic Outcomes. , 2019, International journal of radiation oncology, biology, physics.

[8]  J. Joo,et al.  Effect of Neoadjuvant Hormone Therapy on Resection Margin and Survival Prognoses in Locally Advanced Prostate Cancer after Prostatectomy Using Propensity-Score Matching , 2018, BioMed research international.

[9]  P. Kantoff,et al.  Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade , 2018, Prostate Cancer and Prostatic Diseases.

[10]  Kelvin K. W. Chan,et al.  Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta‐analysis , 2018, International journal of cancer.

[11]  R. Cress,et al.  Nine‐year prostate cancer survival differences between aggressive versus conservative therapy in men with advanced and metastatic prostate cancer , 2018, Cancer.

[12]  F. Montorsi,et al.  Neoadjuvant and adjuvant treatment in high-risk prostate cancer , 2018, Expert review of clinical pharmacology.

[13]  F. Montorsi,et al.  Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. , 2017, European urology.

[14]  B. Czerniecki,et al.  Neoadjuvant radiotherapy of early-stage breast cancer and long-term disease-free survival , 2017, Breast Cancer Research.

[15]  F. Montorsi,et al.  A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. , 2016, European urology.

[16]  L. Fong,et al.  Neoadjuvant therapy for localized prostate cancer: Examining mechanism of action and efficacy within the tumor. , 2016, Urologic oncology.

[17]  R. Laing,et al.  Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019). , 2015, European urology.

[18]  D. Pfister,et al.  Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. , 2015, The Journal of urology.

[19]  P. Schellhammer,et al.  Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. , 2014, European urology.

[20]  J. Moul,et al.  Phase 1 trial of neoadjuvant radiation therapy before prostatectomy for high-risk prostate cancer. , 2013, International journal of radiation oncology, biology, physics.

[21]  Issam El Naqa,et al.  Pelvic normal tissue contouring guidelines for radiation therapy: a Radiation Therapy Oncology Group consensus panel atlas. , 2012, International journal of radiation oncology, biology, physics.

[22]  M. Schell,et al.  Stereotactic body radiation therapy: the report of AAPM Task Group 101. , 2010, Medical physics.

[23]  Tibor Schuster,et al.  Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages , 2010, PLoS medicine.

[24]  M. Makuuchi,et al.  Scenario 1 : Complication After a Surgical Procedure Not Caused by a Surgeon , 2022 .

[25]  H. Scher,et al.  Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer , 2009, Science.

[26]  R. Bristow,et al.  A phase I trial of pre-operative radiotherapy for prostate cancer: clinical and translational studies. , 2008, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[27]  J. Hugosson,et al.  Regressive changes and neuroendocrine differentiation in prostate cancer after neoadjuvant hormonal treatment , 2000, The Prostate.

[28]  K. Pienta,et al.  Oligometastatic prostate cancer: definitions, clinical outcomes, and treatment considerations , 2017, Nature Reviews Urology.

[29]  Deepinder P. Singh,et al.  Is there a favorable subset of patients with prostate cancer who develop oligometastases? , 2004, International journal of radiation oncology, biology, physics.